

October 13, 2021

David Kirn, M.D.
Chief Executive Officer
4D Molecular Therapeutics, Inc.
5858 Horton Street #455
Emeryville, California 94608

Therapeutics, Inc.
Statement on Form S-1
8, 2021

Re: 4D Molecular
Draft Registration
Submitted October
CIK No. 0001650648

Dear Dr. Kirn:

This is to advise you
that we do not intend to review your registration statement.

We request that you publicly file your registration statement no
later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and
461 regarding requests for
acceleration. We remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

Davis at 202-551-4385 with any questions.

Please contact Michael

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Mark V. Roeder, Esq.